Patents by Inventor Joelle Le

Joelle Le has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10383879
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 20, 2019
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Publication number: 20190175608
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 20, 2019
    Publication date: June 13, 2019
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Publication number: 20190127359
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: December 18, 2018
    Publication date: May 2, 2019
    Inventors: CRAIG M. CREWS, DENNIS BUCKLEY, ALESSIO CIULLI, WILLIAM L. JORGENSEN, PETER C. GAREISS, INGE VAN MOLLE, JEFFREY GUSTAFSON, HYUN-SEOP TAE, JULIEN MICHEL, DENTON WADE HOYER, ANKE G. ROTH, JOHN DAVID HARLING, IAN EDWARD DAVID SMITH, AFJAL HUSSAIN MIAH, SEBASTIEN ANDRE CAMPOS, JOELLE LE
  • Publication number: 20180325911
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: May 16, 2018
    Publication date: November 15, 2018
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Publication number: 20170157136
    Abstract: The invention is directed to methods of treatment using compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Publication number: 20170081278
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventors: Véronique BIRAULT, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le
  • Publication number: 20170015656
    Abstract: The invention is directed to certain novel compounds. Specifically, crystalline forms of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide and crystalline 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole, along with salts thereof.
    Type: Application
    Filed: August 2, 2016
    Publication date: January 19, 2017
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Patent number: 9540318
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: January 10, 2017
    Assignee: Glaxo Group Limited
    Inventors: Véronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le
  • Publication number: 20160304478
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Inventors: Veronique BIRAULT, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • Publication number: 20160257664
    Abstract: The present invention is directed to crystalline forms of a compound which has retinoid-related orphan receptor gamma (ROR?) modulator activity, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.
    Type: Application
    Filed: October 23, 2014
    Publication date: September 8, 2016
    Inventors: Veronique BIRAULT, Amanda Jennifer CAMPBELL, Stephen Anthony HARRISON, Joelle LE
  • Patent number: 9428452
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: August 30, 2016
    Assignee: Glaxo Group Limited
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • Publication number: 20160237073
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR, Robert David WILLACY
  • Patent number: 9353098
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 31, 2016
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Patent number: 9326987
    Abstract: The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: May 3, 2016
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Patent number: 9269524
    Abstract: The various technologies presented herein relate to the generation of x-rays and other charged particles. A plurality of disparate source materials can be combined on an array to facilitate fabrication of co-located mixed tips (point sources) which can be utilized to form a polychromatic cloud, e.g., a plurality of x-rays having a range of energies and or wavelengths, etc. The tips can be formed such that the x-rays are emitted in a direction different to other charged particles to facilitate clean x-ray sourcing. Particles, such as protons, can be directionally emitted to facilitate generation of neutrons at a secondary target. The various particles can be generated by interaction of a laser irradiating the array of tips. The tips can be incorporated into a plurality of 3D conical targets, the conical target sidewall(s) can be utilized to microfocus a portion of a laser beam onto the tip material.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: February 23, 2016
    Assignee: Sandia Corporation
    Inventor: Nathalie Joelle Le Galloudec
  • Patent number: 9242972
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: January 26, 2016
    Assignee: Glaxo Group Limited
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • Publication number: 20150361039
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 17, 2015
    Inventors: Véronique BIRAULT, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le
  • Publication number: 20150328226
    Abstract: The invention provides a combination comprising compounds of formula (I) or salts thereof, and one or more therapeutic agents.
    Type: Application
    Filed: May 27, 2015
    Publication date: November 19, 2015
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Publication number: 20150299177
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: June 29, 2015
    Publication date: October 22, 2015
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR, Robert David WILLACY
  • Patent number: 9150508
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR? wherein R1 and R2 are independently selected from the group consisting of H, CF3, halo, C1-3alkyl and C1-3-alkoxy; R3 and R4 are independently selected from the group consisting of H, CF3, halo, CH3 and OCH3; R5 is selected from the group consisting of H, CF3, halo, OH, CH2OH, C1-4alkyl, CH2-cyclopropyl and C1-4alkoxy, wherein C1-4alkyl and C1-4alkoxy, may be optionally substituted with one or two OH substituents; R6 is selected from the group consisting of C3-5alkyl and —CH2—C3-4cycloalkyl; R7 is selected from the group consisting of R8 is selected from the group consisting of C1-3alkyl, C1-3alkoxy, CH2CN, CH2OH, OH, CN and halo; R9 is the group —(CHR10)s—(X)t—(CHR10)u—R11; each R10 is independently
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: October 6, 2015
    Assignee: Glaxo Group Limited
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le